The use of pH-triggered leaky heterogeneities on rigid lipid bilayers to improve intracellular trafficking and therapeutic potential of targeted liposomal immunochemotherapy

Biomaterials

Volumn 30, Issue 30, 2009, Pages 6055-6064

  Karve, Shrirang ^a   Alaouie, Ali ^a   Zhou, Yueping ^a   Rotolo, Jimmy ^b   Sofou, Stavroula ^a  

^a POLYTECHNIC UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Heterogeneous membranes; Immunochemotherapy; Liposome; pH triggered

Indexed keywords

ACYL CHAIN; BI-LAYER; BILAYER MEMBRANES; BLOOD CIRCULATION; CANCER CELLS; DOXORUBICIN; HETEROGENEOUS MEMBRANES; IMMUNOCHEMOTHERAPY; INTRACELLULAR TRAFFICKING; LIPID DOMAINS; LIPOSOMAL DOXORUBICIN; NANOMETER SIZE; PH-DEPENDENT; SPECIFIC BINDING; THERAPEUTIC EFFICACY; THERAPEUTIC POTENTIALS; TRIGGERED RELEASE;

CARDIOVASCULAR SYSTEM; CELL MEMBRANES; CHAIN LENGTH; ION EXCHANGE MEMBRANES; LABELS; LIPOSOMES; PHASE INTERFACES;

LIPID BILAYERS;

DOXORUBICIN; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IMMUNOLIPOSOME; LIPID; LIPOSOME; NANOPARTICLE; PENTETATE INDIUM IN 111; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; TRASTUZUMAB;

ARTICLE; BILAYER MEMBRANE; BINDING AFFINITY; CANCER CELL; CELL KILLING; CHEMOTHERAPY; CIRCULATION TIME; CONTROLLED STUDY; ENCAPSULATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INTERNALIZATION; INTRACELLULAR TRANSPORT; LIPID BILAYER; LIPID VESICLE; MEMBRANE PERMEABILITY; PH; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; COMBINED MODALITY THERAPY; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG THERAPY; ENDOCYTOSIS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOTHERAPY; LIPID BILAYERS; LIPIDS; LIPOSOMES; MICE; MICE, INBRED BALB C; POLYETHYLENE GLYCOLS;

EID: 69249210919     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.07.038     Document Type: Article

References (42)

1. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Cancer Rev 2 (2002) 750-763
2. Sofou S. Surface-active liposomes for targeted cancer therapy. Nanomedicine 2 (2007) 711-724
3. Park J.W., Benz C.C., and Martin F.J. Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31 Suppl. 13 (2004) 196-205
4. Park J.W., Hong K., Carter P., Asgari H., Guo L.Y., Keller G.A., et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. PNAS 92 5 (1995) 1327-1331
5. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8 4 (2002) 1172-1181
6. de Gennes P.G. Conformations of polymers attached to an interface. Macromolecules 13 (1980) 1069-1075
7. Dos Santos N., Allen C., Doppen A.-M., Anantha M., Cox K.A.K., Gallagher R.C., et al. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta (BBA) - Biomembranes 1768 6 (2007) 1367-1377
8. Kenworthy A.K., Simon S.A., and McIntosh T.J. Structure and phase behavior of lipid suspensions containing phospholipids with covalently attached poly(ethylene glycol). Biophys J 68 5 (1995) 1903-1920
9. Yatvin M.B., Kreutz W., Horwitz B.A., and Shinitzky M. pH-sensitive liposomes: possible clinical implications. Science 210 4475 (1980) 1253-1255
10. Ishida T., Kirchmeier M.J., Moase E.H., Zalipsky S., and Allen T.M. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta (BBA) - Biomembranes 1515 2 (2001) 144-158
11. Kirchmeier M.J., Ishida T., Chevrette J., and Allen T.M. Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. J Lipid Res 11 1 (2001) 15-29
12. Alaouie A., and Sofou S. Liposomes with triggered content release for cancer therapy. J Biomed Nanotechnol 4 (2008) 234-244
13. Boggs J.M. Lipid intermolecular hydrogen bonding: influence on structural organization and membrane function. Biochim Biophys Acta 906 (1987) 353-404
14. Drummond D.D., Zignani M., and Leroux J.C. Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 39 (2000) 409-460
15. Garidel P., Johann C., and Blume A. Nonideal mixing and phase separation in phosphatidylcholine-phosphatidic acid mixtures as a function of acyl chain length and pH. Biophys J 72 (1997) 2196-2210
16. Karve S., Bajagur Kempegowda G., and Sofou S. Heterogeneous domains and membrane permeability in phosphatidylcholine-phosphatidic acid rigid vesicles as a function of pH and lipid chain mismatch. Langmuir 24 (2008) 5679-5688
17. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. PNAS 95 (1998) 4607-4612
18. Jain R.K., Munn L.L., and Fukumura D. Dissecting tumor pathophysiology using intravital microscopy. Nat Rev Cancer 2 (2002) 266-276
19. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., et al. Early phase tumor accumulation of macromolecules: a great difference between the tumor vs. normal tissue in their clearance rate. Jpn J Cancer Res 89 (1998) 307-314
20. Stensrud G., Redford K., Smistad G., and Karlsen J. Effects of gamma irradiation on solid and lyophilised phospholipids. Rad Phys Chem 56 (1999) 611-622
21. Haran G., Cohen R., Bar L.K., and Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1151 (1993) 201-215
22. Allen T.M., and Cleland L.G. Serum induced leakage of liposome contents. Biochim Biophys Acta 597 (1980) 418-426
23. Chiu G.N.C., Abraham S.A., Ickenstein L.M., Ng R., Karlsson G., Edwards K., et al. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Controlled Release 104 2 (2005) 271-288
24. Sofou S., Thomas J.L., Lin H.-Y., McDevitt M.R., Scheinberg D.A., and Sgouros G. Engineered liposomes for potential α-particle therapy of metastatic cancer. J Nucl Med 45 (2004) 253-260
25. Provencher S.W. A constrained regularization method for inverting data represented by linear algebraic or integral equations. Comput Phys Commun 27 (1982) 213-227
26. Teraoka I. Polymer solutions: an introduction to physical properties. 1st ed. (2002), John Wiley & Sons, New York, NY
27. Mujoo K., Maneval D.C., Anderson S.C., and Gutterman J.U. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 12 (1996) 1617-1623
28. Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., and Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1237 (1995) 99-108
29. Chang M.-Y., Seideman J., and Sofou S. Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases. Bioconjugate Chem 19 6 (2008) 1274-1282
30. Kirpotin D.B., Park J.W., Hong S.K., Zalipsky S., Li W.-L., Carter P., et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36 (1997) 66-75
31. Kenworthy A.K., Hristova K., Needham D., and McIntosh T.J. Range and magnitude of the steric pressure between bilayers containing phospholipids with covalently attached poly(ethylene glycol). Biophys J 68 (1995) 1921-1936
32. Dean G.S., Pusztai L., Xu F.J., O'Briant K., DeSombre K., Conaway M., et al. Cell surface density of p185c-erbB-2 determines susceptibility to anti-p185c-erbB-2-Ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170EGFR-RTA in ovarian cancer cells. Clin Cancer Res 4 (1998) 2545-2550
33. Eliaz R.E., Nir S., Marty C., and Szoka Jr. F.C. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res 64 2 (2004) 711-718
34. Mellman I. The importance of being acid: the role of acidification in intracellular membrane traffic. J Exp Biol 172 1 (1992) 39-45
35. Dos Santos N., Mayer L.D., Abraham S.A., Gallagher R.C., Cox K.A.K., Tardi P.G., et al. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta (BBA) - Biomembranes 1561 2 (2002) 188-201
36. Marsh D., Bartucci R., and Sportelli L. Lipid membranes with grafted polymers: physicochemical aspects. Biochim Biophys Acta 1615 (2003) 33-59
37. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 9 (2007) E128-E147
38. Singal P.K., and Natasha I. Doxorubicin-induced cardiomyopathy. N Engl J Med 339 (1998) 900-905
39. Laginha K.M., Verwoert S., Charrois G.J.R., and Allen T.M. Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 11 19 (2005) 6944-6949
40. Gabizon A., Goren D., Horowitz A.T., Tzemach D., Lossos A., and Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 24 2-3 (1997) 337-344
41. Gerasimov O.V., Boomer J.A., Qualls M.M., and Thompson D.H. Cytosolic drug delivery using pH- and light-sensitive liposomes. Adv Drug Deliv Rev 38 (1999) 317-338
42. Simoes S., Moreira J.N., Fonseca C., Düzgünes N., and Pedroso de Lima M. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 56 (2004) 947-965